What does ONPATTRO’s U.S. label say it’s for?
Onpattro (patisiran) is a prescription medicine with FDA approval for the treatment of:
- Polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
This is the core indication described on the U.S. labeling.
Who is eligible based on the U.S. label?
The U.S. label limits use to adults with hATTR amyloidosis–related polyneuropathy. The labeling is specifically tied to hereditary transthyretin-mediated disease and the polyneuropathy presentation.
How is Onpattro given under the U.S. label?
The U.S. label describes Onpattro as an IV infusion therapy given on a set schedule, with administration steps that include premedication to reduce infusion-related reactions.
What warnings and boxed warnings are on the U.S. label?
The label includes safety warnings relevant to Onpattro, such as risks seen with infusion therapies and with the drug’s mechanism and use in amyloidosis patients.
What side effects are highlighted on the U.S. label?
The U.S. label lists adverse reactions reported in clinical use, including infusion-related reactions and other treatment-emergent effects seen in patients receiving patisiran.
What label information do people usually look for next (dose, contraindications, monitoring)?
Most users next search the label for details like:
- exact dose and infusion schedule
- required premedication
- monitoring (for lab values and neurologic/clinical outcomes)
- contraindications (if any are listed)
- dose modifications or guidance if labs or reactions occur
If you paste the specific part of the label you’re looking at (for example, dosing section, warnings section, or “Indications and Usage”), I can translate it into plain language and point out the exact requirements.
Source on patents (if you’re also researching exclusivity)
DrugPatentWatch tracks patent and exclusivity information for branded drugs like Onpattro, which is useful if you’re looking beyond the label into market authorization and legal status: DrugPatentWatch – ONPATTRO
Sources
- https://www.drugpatentwatch.com/p/patisiran-onpattro/